Market Closed -
Bombay S.E.
06:00:51 2024-05-23 am EDT
|
5-day change
|
1st Jan Change
|
497.2
INR
|
+2.69%
|
|
-0.32%
|
+23.12%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,879
|
4,419
|
1,310
|
3,558
|
6,966
|
6,954
|
Enterprise Value (EV)
1 |
4,258
|
4,651
|
1,587
|
3,797
|
7,052
|
6,712
|
P/E ratio
|
23.6
x
|
17.5
x
|
19.1
x
|
16.6
x
|
17.2
x
|
14.7
x
|
Yield
|
1.14%
|
1%
|
-
|
1.24%
|
0.63%
|
0.64%
|
Capitalization / Revenue
|
2.14
x
|
2.08
x
|
0.72
x
|
1.69
x
|
2.5
x
|
2.18
x
|
EV / Revenue
|
2.35
x
|
2.18
x
|
0.88
x
|
1.8
x
|
2.53
x
|
2.1
x
|
EV / EBITDA
|
9.35
x
|
8
x
|
5.22
x
|
7.06
x
|
8.71
x
|
7.01
x
|
EV / FCF
|
-48.3
x
|
28.7
x
|
17.7
x
|
239
x
|
41.5
x
|
27.5
x
|
FCF Yield
|
-2.07%
|
3.48%
|
5.66%
|
0.42%
|
2.41%
|
3.64%
|
Price to Book
|
2.55
x
|
2.58
x
|
0.76
x
|
1.83
x
|
2.98
x
|
2.47
x
|
Nbr of stocks (in thousands)
|
22,108
|
22,108
|
22,108
|
22,108
|
22,108
|
22,129
|
Reference price
2 |
175.4
|
199.9
|
59.25
|
161.0
|
315.1
|
314.2
|
Announcement Date
|
8/1/18
|
7/3/19
|
8/14/20
|
6/8/21
|
5/30/22
|
6/1/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,811
|
2,130
|
1,811
|
2,110
|
2,787
|
3,190
|
EBITDA
1 |
455.4
|
581
|
303.8
|
537.4
|
809.7
|
957.6
|
EBIT
1 |
298.4
|
383.8
|
94.52
|
306.6
|
576.4
|
650.4
|
Operating Margin
|
16.47%
|
18.02%
|
5.22%
|
14.53%
|
20.68%
|
20.39%
|
Earnings before Tax (EBT)
1 |
255.6
|
351.4
|
82.7
|
285.4
|
556.8
|
650
|
Net income
1 |
164.3
|
253.1
|
68.45
|
214
|
413.3
|
481.7
|
Net margin
|
9.07%
|
11.88%
|
3.78%
|
10.14%
|
14.83%
|
15.1%
|
EPS
2 |
7.430
|
11.45
|
3.096
|
9.680
|
18.32
|
21.35
|
Free Cash Flow
1 |
-88.23
|
161.9
|
89.87
|
15.88
|
169.8
|
244.1
|
FCF margin
|
-4.87%
|
7.6%
|
4.96%
|
0.75%
|
6.09%
|
7.65%
|
FCF Conversion (EBITDA)
|
-
|
27.87%
|
29.58%
|
2.96%
|
20.98%
|
25.49%
|
FCF Conversion (Net income)
|
-
|
63.97%
|
131.29%
|
7.42%
|
41.1%
|
50.67%
|
Dividend per Share
2 |
2.000
|
2.000
|
-
|
2.000
|
2.000
|
2.000
|
Announcement Date
|
8/1/18
|
7/3/19
|
8/14/20
|
6/8/21
|
5/30/22
|
6/1/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
380
|
232
|
278
|
238
|
85.4
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
242
|
Leverage (Debt/EBITDA)
|
0.8336
x
|
0.3986
x
|
0.9133
x
|
0.4434
x
|
0.1055
x
|
-
|
Free Cash Flow
1 |
-88.2
|
162
|
89.9
|
15.9
|
170
|
244
|
ROE (net income / shareholders' equity)
|
11.4%
|
15.6%
|
3.97%
|
11.7%
|
19.3%
|
18.7%
|
ROA (Net income/ Total Assets)
|
8.22%
|
10.2%
|
2.45%
|
7.37%
|
12.4%
|
12.1%
|
Assets
1 |
2,000
|
2,478
|
2,799
|
2,905
|
3,336
|
3,967
|
Book Value Per Share
2 |
68.80
|
77.60
|
78.20
|
87.90
|
106.0
|
127.0
|
Cash Flow per Share
2 |
0.9000
|
1.210
|
2.490
|
2.800
|
4.890
|
13.80
|
Capex
1 |
243
|
165
|
158
|
331
|
298
|
478
|
Capex / Sales
|
13.44%
|
7.76%
|
8.72%
|
15.68%
|
10.68%
|
14.99%
|
Announcement Date
|
8/1/18
|
7/3/19
|
8/14/20
|
6/8/21
|
5/30/22
|
6/1/23
|
|
1st Jan change
|
Capi.
|
---|
| +23.12% | 129M | | -31.95% | 9.87B | | -16.78% | 2.75B | | -15.31% | 2.13B | | -23.99% | 1.65B | | +68.17% | 1.47B | | +31.96% | 811M | | -5.02% | 733M | | -30.10% | 510M | | +1.59% | 300M |
Bio Diagnostics & Testing
|